论文部分内容阅读
近年来,大量循证医学研究成果表明,急性ST段抬高心肌梗死(STEMI)患者应得到及时的再灌注治疗,而在实施再灌注治疗的基础上早期应用低分子肝素、β受体阻滞剂、血管紧张素转换酶抑制剂(ACEI)、他汀类调脂药、阿司匹林、氯吡格雷等药物可提高患者生存率,而且我国及ACC/AHA急性心肌梗死(AMI)治疗指南中均强调了这些治疗的必要性。本
In recent years, a large number of evidence-based medical research shows that acute ST-elevation myocardial infarction (STEMI) patients should be timely reperfusion treatment, and in the implementation of reperfusion therapy based on the early application of low molecular weight heparin, β block Agents, angiotensin-converting enzyme inhibitors (ACEIs), statins lipid-lowering drugs, aspirin, clopidogrel and other drugs can improve patient survival, but also in our country and ACC / AHA guidelines for the treatment of acute myocardial infarction (AMI) Necessity of these treatments. this